Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab add-on after progression on first-line PD-(L)1 plus anti-angiogenic therapy for advanced hepatocellular carcinoma
ChiCTR2400082750Phase 4Recruiting
- Sponsor
- Shanghai GoBroad Cancer Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ipilimumab in hepatocellular carcinoma (HCC), sponsored by Shanghai GoBroad Cancer Hospital. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400082750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082750.